Lung Cancer Treatment in China: What the Panel Changes, What a City Package Doesn't
Lung cancer in China is a molecular-plan problem. IARC GLOBOCAN 2024: 1,175,915 new cases and 743,336 deaths. EGFR mutations are more common in China than in Europe (38.4% vs 14.1% of NSCLC patients in a 2016 meta-analysis). Send histology and EGFR/ALK/ROS1/PD-L1. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
1.18 million casesIARC 2024 China
EGFR first38.4% in China (meta-analysis)
No lung packagepanel or no shortlist
Quick answer
Lung cancer in China is a molecular-plan problem, not a city package. IARC GLOBOCAN 2024: 1,175,915 new cases and 743,336 deaths — first in both. EGFR mutations are more common in China than in Europe (38.4% vs 14.1% of NSCLC patients in a 2016 meta-analysis of 456 studies). NCI lists osimertinib alone, osimertinib plus chemotherapy and amivantamab plus lazertinib among first-line options for EGFR-mutated disease; the NCCN NSCLC guideline in force at our 24 October 2026 check was Version 9.2026. CAR-T is not standard lung-cancer care. Send histology and EGFR/ALK/ROS1/PD-L1. About 24 hours. No obligation to book.
Lung: what the file must split
NSCLC vs SCLC
Different disease. A mixed ‘lung package’ is not a plan.
Minimum panel
EGFR, ALK, ROS1, PD-L1. Broader NGS (KRAS, MET, RET, BRAF) when possible.
Not standard here
CAR-T for lung = trial only. Proton = selected geometry, not metastatic spray.
| Question | Usual comparison | Cost note |
|---|---|---|
| Molecular NSCLC / IO | CAMS/NCC, Fudan, SYSUCC, PKU Cancer, Tianjin | Drugs dominate — no single band |
| Selected proton / re-irradiation | SPHIC, Ruijin — imaging first | Cost depends on the centre and plan; ask for a written quote |
| ‘Lung CAR-T’ ad | Treat as trial until named | Do not use blood-cancer CAR-T prices |
What actually changes the plan
📋
Molecular profile first
NSCLC vs SCLC, then EGFR/ALK/ROS1/KRAS/MET/RET/PD-L1. No panel, no serious shortlist.
🏥
Thoracic department, not a brand
CAMS/NCC, Fudan, SYSUCC, Tianjin, PKU Cancer. SPHIC only if the geometry needs a beam.
✈️
Drug and stay drivers
Targeted/IO lines and inpatient days move the bill. We will not quote a lung package from a screenshot.
What this page helps you decide
✅
NSCLC and SCLC split
We do not mix small-cell protocols into an adenocarcinoma brochure.
💬
CAR-T labelled as trial-only here
Lung is not the blood-cancer CAR-T page. We say no when an ad says otherwise.
🌍
Stage-4 goals in writing
Control and symptoms when cure is not the endpoint.
Evidence table
IARC lung burden, current first-line EGFR options, EGFR prevalence in China vs Europe.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | 1,175,915 cases; 743,336 deaths | Volume is real. Not a ranking of your file. |
| NCCN NSCLC (Version 9.2026, checked 24 Oct 2026) | Full panel first; check the plan against the current version | No panel, no honest shortlist. |
| EGFR meta-analysis, 456 studies (Oncotarget 2016) | EGFR 38.4% China vs 14.1% Europe | Why an Asian lung file without EGFR is incomplete. |
| CSCO NSCLC (2025) | 3rd-generation EGFR-TKI preferred class | Domestic TKIs exist; they still need the mutation. |
Who this page is for
NSCLC with a driver mutation
Need a centre that will treat the molecular report, not a generic ablation package.
SCLC or biomarker-negative NSCLC
Need an honest systemic plan and stage-4 goals, not a sold 'China cure'.
Families comparing targeted-drug quotes
Need the same line compared across hospitals, including what the drug costs extra.
What you can actually book
Public thoracic volume: CAMS/NCC, PKU Cancer, FUSCC, Shanghai Chest, SYSUCC, Guangdong Lung Cancer Institute. SPHIC only for a defined beam. Related: cancer hub, proton.
How lung cancer is treated, and which tests come first
The treatment plan for lung cancer depends on the tumour type (non-small cell or small cell), the stage and the tumour’s molecular markers. Below is a short summary of how international and Chinese guidelines approach this. An oncologist proposes the actual plan after reviewing the pathology, test results and scans.
Tests needed before treatment
Lung cancer is confirmed by biopsy, for example with a fine needle guided by CT or during bronchoscopy. In non-small cell cancer, the same tissue is tested for molecular markers, which decide whether treatment can start with targeted tablets instead of chemotherapy.
EGFR, ALK, ROS1, BRAF, NTRK
International guidelines say testing for markers with available drugs is mandatory.
KRAS, MET, RET, HER2
These are tested too, most conveniently with one broad genetic panel (NGS) where available.
PD-L1
At stage IV everyone needs a PD-L1 test. The result should be given as a percentage, because it decides which immunotherapy is discussed.
Blood test for tumour DNA
Helps find mutations when there is little tissue, and find out why a targeted drug stopped working. But if the blood test finds no mutation, a tissue biopsy is still needed.
With metastatic disease the brain is usually checked as well, and it must be checked if there are neurological symptoms. Contrast MRI is preferred.
Targeted drugs by marker
The table lists drugs discussed for non-small cell cancer with a known marker. China has registered both international drugs and its own.
| Marker in your report | Drugs registered in China | Good to know |
|---|---|---|
| EGFR (exon 19 deletion or L858R) | Osimertinib (including with chemotherapy), aumolertinib, furmonertinib | International guidelines prefer osimertinib, especially with brain metastases |
| EGFR, growth on a targeted drug | Sacituzumab tirumotecan, ivonescimab (non-squamous cancer) | The cause of resistance is checked first, with a repeat biopsy or a blood test |
| EGFR, exon 20 insertion | Sunvozertinib, amivantamab with chemotherapy | The mutation must be confirmed by testing |
| ALK | Ensartinib, iruplinalkib | International guidelines prefer alectinib, brigatinib or lorlatinib first |
| ROS1 | Taletrectinib | International guidelines use crizotinib or entrectinib first |
| KRAS G12C | Fulzerasib, garsorasib, glecirasib | After at least one line of treatment |
| MET, exon 14 skipping | Savolitinib | Including for people not yet treated |
| RET | Pralsetinib, selpercatinib | Recommended from the start of treatment |
| BRAF V600 | Dabrafenib + trametinib | The two-drug combination is recommended |
| HER2, mutation | Trastuzumab rezetecan, zongertinib | Zongertinib since 2026 also as first treatment |
| NTRK, gene fusion | Larotrectinib | Rare; discussed when there are no other good options |
| No EGFR or ALK, PD-L1 1% or more | Ivonescimab without chemotherapy | With PD-L1 of 50% or more, single-drug immunotherapy is possible |
Registration does not mean a drug suits a given case: the oncologist decides based on the marker, stage and treatment history.
Immunotherapy
When there is no targetable marker, stage IV treatment most often involves immunotherapy, alone or with chemotherapy. The choice depends largely on the PD-L1 level.
Small cell lung cancer
It is divided into limited and extensive stage. In limited stage, chemotherapy with chest radiotherapy is followed by durvalumab immunotherapy; this is registered in China. In extensive stage, the base is immunotherapy with chemotherapy, and China also has its own drugs for this. At relapse, options include lurbinectedin and tarlatamab; registration of tarlatamab in China is not yet complete.
Radiotherapy instead of surgery at an early stage
Stereotactic radiotherapy delivers a high dose in 1–5 sessions over 1–2 weeks. It is widely used for stage I when surgery is not possible for health reasons. When surgery is possible and the risk is standard, replacing it with radiotherapy outside a study is not recommended. A biopsy is done before treatment where possible.
Brain metastases
If brain metastases cause symptoms, local treatment is needed: radiosurgery, radiotherapy or surgery. If there are no symptoms and the tumour has an EGFR or ALK change, treatment can start with a targeted drug (osimertinib for EGFR; alectinib, brigatinib or ceritinib for ALK), and local treatment can wait until the brain lesions grow. This decision is made by a tumour board.
Clinical trials in China
You can join a trial only if you meet its criteria: cancer type and stage, previous treatment, age, general health and other illnesses. That is why participation cannot be promised in advance: your documents are first checked against available trials, and the trial centre makes the decision.
Documents to send
- Pathology report: the cancer type, and if you had surgery, the report on the removed tissue.
- Molecular test results or a genetic panel report, and the PD-L1 result as a number.
- The report of any blood test for tumour DNA.
- Chest CT, PET-CT and brain MRI as DICOM files, with the reports.
- A list of treatment so far: drugs, dates and response; surgery and radiotherapy reports.
An oncologist will review the documents free of charge and tell you which options are realistic in your case.
Sources: international clinical guidelines (ESMO, ASCO, IASLC, ASTRO), Chinese Society of Clinical Oncology guidelines, official drug registration data in China.
What moves the cost
Lung file review
No charge to start
NSCLC/SCLC split • Biomarker gaps • Centre shortlist • Cost-driver note
Coordinated trip
Quoted after records
Hospital matching • Drug/stay drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send histology and NGS
Plus staging imaging and prior systemic lines. Missing EGFR/ALK/PD-L1 restarts the clock.
02
Match department and line
Targeted, IO, chemo, surgery, selected radiation/proton — each labelled.
03
Travel after a centre will see you
Invitation, visa, interpreter. No exploratory flight for a missing molecular report.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is lung cancer treatment in China?
It depends on the driver. EGFR TKIs, immunotherapy, surgery and selected proton are different invoices. We itemise after the panel. There is no generic lung package.
Why does EGFR matter more in China?
In a 2016 meta-analysis of 456 studies, EGFR mutations were found in 38.4% of NSCLC patients in China versus 14.1% in Europe. A file without EGFR is incomplete.
Is CAR-T used for lung cancer?
Not as standard of care. Solid-tumour cell programmes need a trial ID.
Which hospitals?
CAMS/NCC, PKU Cancer, FUSCC, Shanghai Chest, SYSUCC, Guangdong Lung Cancer Institute. SPHIC only for a defined beam.
NSCLC or SCLC — does it matter?
Yes. They do not share a protocol.
What records should I send?
Histology, NGS or at least EGFR/ALK/ROS1/PD-L1, staging CT/PET, smoking and performance status, prior lines.
Is proton default for lung?
No.
Do you promise a response rate?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Can a blood test replace a biopsy?
Not completely. A blood test for tumour DNA helps find mutations when there is little tissue, and find out why a targeted drug stopped working. But if the blood test finds no mutation, a tissue biopsy is still needed. If you have had a blood test, include the report with your documents for a free case review.
Can I join a clinical trial in China?
Sometimes, but only if you meet the criteria of a specific trial: cancer type and stage, previous treatment, age, general health and other illnesses. Participation cannot be promised in advance: your documents are first checked against available trials, and the trial centre makes the decision.
Red flags in offers
A “China lung package” or proton as default. Immunotherapy sold on top of an unused TKI. Fuda as the lung hospital. None of that replaces the panel.
Quote without EGFR/ALK/PD-L1.
CAR-T for NSCLC with no trial ID.
One package for SCLC and NSCLC.
Pay before slides and CT are read.
Sources
IARC GLOBOCAN 2024 China fact sheet.
NCCN NSCLC guideline, Version 9.2026 (version in force on 24 October 2026).
NCI PDQ: Non-Small Cell Lung Cancer Treatment (health professional version).
CSCO 2025 NSCLC updates (3rd-gen EGFR-TKI preferred).
Zhang YL et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7(48):78985-78993.
Freshness label on this page: 2026-10-24
Medical note
A treating oncologist should review imaging and pathology before you travel. This page is matching information, not a treatment recommendation.